Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Abstract

Is cancer immunotherapy a private affair? Immune checkpoint blockade, a relatively new cancer treatment, substantially extends the survival of a subset of patients. Previous work has shown that patients whose tumors harbor the largest number of mutations—and thus produce a large number of “neoantigens” recognized as foreign by the immune system—are most likely to benefit. Expanding on these earlier studies, Van Allen et al. studied over 100 patients with melanoma and found a similar correlation (see the Perspective by Gubin and Schreiber). There was no evidence, however, that specific neoantigen sequences were shared by patients who responded. Science , this issue p. 207 , see also p. 158

Keywords

Affiliated Institutions

• German Cancer Research Center DE
• The Netherlands Cancer Institute NL
• Elbe Kliniken Stade-Buxtehude DE
• University of Duisburg-Essen DE
• Deutschen Konsortium für Translationale Krebsforschung
• University Hospital Heidelberg DE
• University Medical Center of the Johannes Gutenberg University Mainz DE
• University Hospital of Zurich CH
• Johannes Gutenberg University Mainz DE
• Dana-Farber Cancer Institute US
• University Children's Hospital Tübingen DE
• Broad Institute US
• Heidelberg University DE
• Medizinische Hochschule Hannover DE

Related Publications